NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that Mordechai (Moti) Friedman, CPA, a former Deloitte Brightman Almagor executive and deputy chairman, has been elected as an independent director of the Company. Mr. Friedman also will serve as the Chairman of the Audit Committee of the Board of Directors.
